SMTL ID : 6umj.1

Crystal structure of erenumab Fab-c

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.70 Å

Oligo State

hetero-1-1-mer

Ligands

1 x BU2: 1,3-BUTANEDIOL(Non-covalent)

BU2.1: 3 residues within 4Å: Chain A: H.35, V.50, D.99 1 PLIP interactions: 1 interactions with chain A Hydrogen bonds: A:D.99

2 x MPD: (4S)-2-METHYL-2,4-PENTANEDIOL(Non-functional Binders)

MPD.2: 7 residues within 4Å: Chain A: K.43, G.44 Chain B: P.8, D.86, Y.88, G.103, G.104 1 PLIP interactions: 1 interactions with chain B Hydrogen bonds: B:D.86 MPD.3: 9 residues within 4Å: Chain A: K.146, S.147, S.149, T.152, A.154 Chain B: T.118, V.119, T.120, K.208 1 PLIP interactions: 1 interactions with chain A Hydrophobic interactions: A:A.154

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Garces, F. et al., Molecular Insight into Recognition of the CGRPR Complex by Migraine Prevention Therapy Aimovig (Erenumab). Cell Rep (2020)

Release Date

2020-02-12

Peptides

erenumab Fab heavy chain, IgG1: A
erenumab Fab light chain, IgG1: B

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
H

B
L

erenumab Fab heavy chain, IgG1

erenumab Fab light chain, IgG1

Related Entries With Identical Sequence